Sustained Drug Release from Smart Nanoparticles in Cancer Therapy: A Comprehensive Review.
cancer nanomedicine
drug delivery systems
liposomes
microfluidics
polymeric nanoparticles
sustained drug release
Journal
Micromachines
ISSN: 2072-666X
Titre abrégé: Micromachines (Basel)
Pays: Switzerland
ID NLM: 101640903
Informations de publication
Date de publication:
28 Sep 2022
28 Sep 2022
Historique:
received:
08
09
2022
revised:
22
09
2022
accepted:
22
09
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
Although nanomedicine has been highly investigated for cancer treatment over the past decades, only a few nanomedicines are currently approved and in the market; making this field poorly represented in clinical applications. Key research gaps that require optimization to successfully translate the use of nanomedicines have been identified, but not addressed; among these, the lack of control of the release pattern of therapeutics is the most important. To solve these issues with currently used nanomedicines (e.g., burst release, systemic release), different strategies for the design and manufacturing of nanomedicines allowing for better control over the therapeutic release, are currently being investigated. The inclusion of stimuli-responsive properties and prolonged drug release have been identified as effective approaches to include in nanomedicine, and are discussed in this paper. Recently, smart sustained release nanoparticles have been successfully designed to safely and efficiently deliver therapeutics with different kinetic profiles, making them promising for many drug delivery applications and in specific for cancer treatment. In this review, the state-of-the-art of smart sustained release nanoparticles is discussed, focusing on the design strategies and performances of polymeric nanotechnologies. A complete list of nanomedicines currently tested in clinical trials and approved nanomedicines for cancer treatment is presented, critically discussing advantages and limitations with respect to the newly developed nanotechnologies and manufacturing methods. By the presented discussion and the highlight of nanomedicine design criteria and current limitations, this review paper could be of high interest to identify key features for the design of release-controlled nanomedicine for cancer treatment.
Identifiants
pubmed: 36295976
pii: mi13101623
doi: 10.3390/mi13101623
pmc: PMC9611581
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Biomaterials. 2005 May;26(15):2713-22
pubmed: 15585275
PDA J Pharm Sci Technol. 2011 Mar-Apr;65(2):131-9
pubmed: 21502074
J Pharm Bioallied Sci. 2014 Jul;6(3):139-50
pubmed: 25035633
Nanomedicine (Lond). 2019 Aug;14(15):2011-2025
pubmed: 31355696
ACS Nano. 2008 Oct 28;2(10):1984-6
pubmed: 19206441
Cancer Sci. 2011 Jan;102(1):192-9
pubmed: 21040218
Signal Transduct Target Ther. 2018 Mar 16;3:7
pubmed: 29560283
Adv Drug Deliv Rev. 2009 Nov 12;61(13):1214-9
pubmed: 19671439
Pharm Res. 2001 Sep;18(9):1331-5
pubmed: 11683249
Int J Pharm. 2011 Aug 30;415(1-2):34-52
pubmed: 21640806
Cancer Res. 2016 Mar 15;76(6):1517-27
pubmed: 26759238
Adv Mater. 2012 Jul 24;24(28):3779-802
pubmed: 22610698
J Control Release. 2005 Feb 2;102(2):333-44
pubmed: 15653155
Int J Nanomedicine. 2019 Nov 01;14:8543-8560
pubmed: 31802868
J Control Release. 2000 Sep 3;68(3):419-31
pubmed: 10974396
Anticancer Res. 2006 Mar-Apr;26(2B):1489-93
pubmed: 16619562
Adv Drug Deliv Rev. 2013 Nov;65(13-14):1667-85
pubmed: 24113520
J Control Release. 2000 Dec 3;69(3):399-412
pubmed: 11102680
Sci Rep. 2017 Dec 21;7(1):18014
pubmed: 29269874
Pharm Dev Technol. 2013 May-Jun;18(3):694-700
pubmed: 22676257
Pharm Res. 2016 Oct;33(10):2373-87
pubmed: 27299311
Invest New Drugs. 2014 Jun;32(3):445-51
pubmed: 24271274
Adv Drug Deliv Rev. 2013 Nov;65(13-14):1699-715
pubmed: 23611952
Int J Nanomedicine. 2012;7:5577-91
pubmed: 23144561
Onco Targets Ther. 2016 May 20;9:3001-7
pubmed: 27284250
Urology. 2003 Feb;61(2 Suppl 1):25-31
pubmed: 12667884
Bioimpacts. 2011;1(3):145-7
pubmed: 23678419
Biotechnol J. 2018 Jan;13(1):
pubmed: 28941234
Bioeng Transl Med. 2016 Jun 03;1(1):10-29
pubmed: 29313004
J Control Release. 2005 Mar 2;103(1):83-91
pubmed: 15710502
Int J Nanomedicine. 2017 Jan 27;12:935-947
pubmed: 28184163
Invest New Drugs. 2011 Dec;29(6):1465-74
pubmed: 20499131
Molecules. 2017 Aug 23;22(9):
pubmed: 28832535
Pharmaceutics. 2019 Nov 08;11(11):
pubmed: 31717376
J Pharm Sci. 2017 Feb;106(2):511-520
pubmed: 27832839
J Adv Res. 2018 Jun 25;15:1-18
pubmed: 30581608
Pharmaceutics. 2021 Sep 03;13(9):
pubmed: 34575472
Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11613-8
pubmed: 18697944
J Pharm Pharmacol. 2012 Jan;64(1):61-7
pubmed: 22150673
Adv Drug Deliv Rev. 2013 Jan;65(1):80-8
pubmed: 23036224
Recent Pat Drug Deliv Formul. 2012 Dec;6(3):209-23
pubmed: 22734869
Food Chem Toxicol. 2013 Feb;52:200-6
pubmed: 23149094
Int J Nanomedicine. 2013;8:3309-19
pubmed: 24023517
Discov Med. 2013 Feb;15(81):101-10
pubmed: 23449112
Eur J Pharmacol. 2022 Jan 15;915:174512
pubmed: 34555395
Acc Chem Res. 2011 Oct 18;44(10):1123-34
pubmed: 21692448
Cancer Chemother Pharmacol. 2014 Feb;73(2):363-71
pubmed: 24297683
Colloids Surf B Biointerfaces. 2017 Nov 1;159:217-231
pubmed: 28797972
Drug Dev Ind Pharm. 2014 Mar;40(3):409-17
pubmed: 23480566
Invest New Drugs. 2006 Nov;24(6):521-7
pubmed: 16699974
Mol Ther. 2014 Sep;22(9):1643-52
pubmed: 24569836
Expert Opin Investig Drugs. 2006 Jul;15(7):815-22
pubmed: 16787144
Int J Oncol. 2007 Nov;31(5):1243-50
pubmed: 17912453
Cell Mol Life Sci. 2014 Apr;71(8):1417-38
pubmed: 24221135
J Control Release. 2018 May 10;277:126-141
pubmed: 29534890
Crit Rev Ther Drug Carrier Syst. 1999;16(3):245-88
pubmed: 10706520
Int J Nanomedicine. 2019 May 23;14:3819-3830
pubmed: 31213803
Expert Opin Biol Ther. 2010 May;10(5):819-32
pubmed: 20384524
J Control Release. 2011 Apr 30;151(2):131-8
pubmed: 21362449
Nat Nanotechnol. 2008 Jul;3(7):423-8
pubmed: 18654567
J Control Release. 2017 Jul 28;258:226-253
pubmed: 28472638
Drug Deliv. 2016;23(3):787-93
pubmed: 24870204
J Control Release. 2012 Jul 20;161(2):505-22
pubmed: 22353619
Nanotechnology. 2013 Jun 21;24(24):245101
pubmed: 23702815
Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):169-85
pubmed: 11259839
ACS Nano. 2009 Oct 27;3(10):2919-26
pubmed: 19772302
Int J Mol Sci. 2016 May 23;17(5):
pubmed: 27223283
Int J Nanomedicine. 2018 May 18;13:2921-2942
pubmed: 29849457
Nat Biomed Eng. 2018 Nov;2(11):797-809
pubmed: 30931172
Int J Mol Sci. 2018 Dec 04;19(12):
pubmed: 30518027
Biomaterials. 2010 Nov;31(33):8741-8
pubmed: 20727587
Cancer Chemother Pharmacol. 2013 Mar;71(3):555-64
pubmed: 23212117
Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15344-9
pubmed: 25316794
Mol Clin Oncol. 2014 Nov;2(6):904-908
pubmed: 25279172
Lancet Oncol. 2019 Aug;20(8):1148-1159
pubmed: 31296491
J Drug Target. 2008 Jun;16(5):424-35
pubmed: 18569287
Int J Nanomedicine. 2011;6:3021-32
pubmed: 22162659
Clin Pharmacol Ther. 2014 Feb;95(2):168-78
pubmed: 24013811
Chem Rev. 2016 Feb 24;116(4):2602-63
pubmed: 26854975
Clin Cancer Res. 2005 Aug 1;11(15):5487-95
pubmed: 16061865
J Control Release. 2018 Aug 28;284:39-48
pubmed: 29902484
Life (Basel). 2021 Jan 19;11(1):
pubmed: 33478036
Pharmacol Res. 2019 Jan;139:91-105
pubmed: 30408575
Int J Nanomedicine. 2014 Jun 25;9:3107-18
pubmed: 25028549
Nat Rev Cancer. 2017 Jan;17(1):20-37
pubmed: 27834398
Adv Drug Deliv Rev. 2016 Dec 15;107:213-227
pubmed: 27423636
Daru. 2013 Jul 17;21(1):58
pubmed: 23866721
Int J Pharm. 2020 Nov 30;590:119926
pubmed: 33010397
Biomed Res Int. 2017;2017:8589212
pubmed: 28246606
Cancer Immunol Immunother. 2018 Sep;67(9):1461-1472
pubmed: 30014244
Pharmaceutics. 2017 Mar 27;9(2):
pubmed: 28346375
Nat Mater. 2013 Nov;12(11):991-1003
pubmed: 24150417
AAPS J. 2015 Sep;17(5):1041-54
pubmed: 25956384
Nanomedicine. 2009 Dec;5(4):419-23
pubmed: 19523421
Adv Drug Deliv Rev. 2008 Jan 3;60(1):50-8
pubmed: 17822802
J Control Release. 2014 Aug 10;187:133-44
pubmed: 24874289
Acta Biomater. 2013 Dec;9(12):9243-57
pubmed: 23958782
Chempluschem. 2020 Sep;85(9):2143-2157
pubmed: 32864902
ACS Nano. 2008 Mar;2(3):538-44
pubmed: 19206580
Polymers (Basel). 2011 Sep 1;3(3):1377-1397
pubmed: 22577513
J Control Release. 2010 Dec 1;148(2):135-46
pubmed: 20797419
Nanoscale. 2014 Nov 7;6(21):12273-86
pubmed: 25251024
Oncotarget. 2016 Nov 22;7(47):77348-77357
pubmed: 27764799
Adv Drug Deliv Rev. 2011 Mar 18;63(3):184-92
pubmed: 20561951
Cancer Res. 1986 Dec;46(12 Pt 1):6387-92
pubmed: 2946403
Drug Discov Today. 2017 Feb;22(2):270-281
pubmed: 27890669
J Thorac Oncol. 2006 Nov;1(9):984-90
pubmed: 17409983
Adv Drug Deliv Rev. 2012 Dec;64(15):1730-7
pubmed: 22732527
Int J Pharm. 2003 Dec 11;268(1-2):71-9
pubmed: 14643978
Hum Gene Ther. 2018 Nov;29(11):1227-1234
pubmed: 29893153
J Clin Oncol. 2014 Dec 20;32(36):4141-8
pubmed: 25403217
Nanomedicine. 2015 Feb;11(2):301-11
pubmed: 25240597
Int J Pharm. 2006 Jan 3;307(1):93-102
pubmed: 16303268
Int J Nanomedicine. 2012;7:1697-708
pubmed: 22619520
Nano Today. 2019 Apr;25:85-98
pubmed: 31360214
Drug Discov Today. 2018 May;23(5):1108-1114
pubmed: 29408437
Trends Biotechnol. 2017 Feb;35(2):159-171
pubmed: 27492049
Mol Pharm. 2019 Mar 4;16(3):1140-1155
pubmed: 30668131
Res Pharm Sci. 2019 Oct 04;14(5):459-470
pubmed: 31798663
Pharmaceutics. 2020 Aug 31;12(9):
pubmed: 32878127
Br J Cancer. 2002 Jul 1;87(1):15-20
pubmed: 12085249
J Biomater Sci Polym Ed. 2005;16(8):991-1007
pubmed: 16128233
Nanomedicine (Lond). 2014 Jan;9(1):121-34
pubmed: 24354814
Theranostics. 2016 Jun 15;6(9):1393-402
pubmed: 27375787
Mol Cancer Ther. 2006 Aug;5(8):1909-17
pubmed: 16928810
J Pharm Sci. 2020 Jan;109(1):104-115
pubmed: 31669121
Clin Transl Med. 2017 Dec 11;6(1):44
pubmed: 29230567
Adv Mater. 2009 Nov 20;21(43):4339-42
pubmed: 26042940
Eur J Cancer. 2010 Nov;46(16):3016-21
pubmed: 20801016
Cancer. 2002 Jul 15;95(2):389-96
pubmed: 12124839
Front Pharmacol. 2019 Dec 18;10:1450
pubmed: 31920645
Cancers (Basel). 2019 Aug 28;11(9):
pubmed: 31466358
BioDrugs. 2008;22(5):315-29
pubmed: 18778113
Nat Nanotechnol. 2012 Oct;7(10):623-9
pubmed: 23042546
Clin Cancer Res. 2004 May 15;10(10):3386-95
pubmed: 15161693
Toxicol Appl Pharmacol. 2005 Sep 15;207(3):221-31
pubmed: 16129115
Langmuir. 2011 Sep 6;27(17):10556-61
pubmed: 21806013
Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2586-91
pubmed: 18272481
J Control Release. 2012 Jun 10;160(2):117-34
pubmed: 22484195
Br J Cancer. 2004 Jul 5;91(1):50-5
pubmed: 15187995
J Pers Med. 2021 Mar 22;11(3):
pubmed: 33810037
Bioconjug Chem. 2017 Oct 18;28(10):2591-2598
pubmed: 28872851
J Am Chem Soc. 2009 Apr 8;131(13):4744-54
pubmed: 19281160
Pharmaceutics. 2020 Sep 10;12(9):
pubmed: 32927610
Colloids Surf B Biointerfaces. 2015 Jun 1;130:229-36
pubmed: 25937384
Int J Pharm. 2021 Jul 15;604:120711
pubmed: 34015381
Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11901-4
pubmed: 17620615
Nat Nanotechnol. 2016 Nov;11(11):986-994
pubmed: 27668795
BMC Cancer. 2017 Mar 6;17(1):172
pubmed: 28264666
J Control Release. 2015 Dec 10;219:205-214
pubmed: 26341694
Materials (Basel). 2020 Mar 25;13(7):
pubmed: 32218241
Eur J Pharm Biopharm. 2004 Sep;58(2):445-55
pubmed: 15296966
Nature. 2006 Jul 27;442(7101):368-73
pubmed: 16871203
Pharm Res. 2003 Nov;20(11):1864-72
pubmed: 14661934
Cancer Chemother Pharmacol. 2007 Sep;60(4):523-33
pubmed: 17308894
J Control Release. 2017 Sep 10;261:163-173
pubmed: 28662900
Pharmaceutics. 2021 Jul 02;13(7):
pubmed: 34371702
Acta Biomater. 2012 Aug;8(8):2996-3004
pubmed: 22561668
Sci Transl Med. 2012 Apr 4;4(128):128ra39
pubmed: 22491949
Int J Nanomedicine. 2016 Mar 02;11:853-71
pubmed: 27042053
Colloids Surf B Biointerfaces. 2017 Feb 1;150:408-416
pubmed: 27829536
ACS Appl Bio Mater. 2020 Jan 21;3(1):107-120
pubmed: 35019430
Int J Nanomedicine. 2014 Jun 19;9:3005-12
pubmed: 24971011
Int J Radiat Oncol Biol Phys. 2016 Nov 1;96(3):547-55
pubmed: 27681751
Clin Cancer Res. 2004 Nov 1;10(21):7244-51
pubmed: 15534098
Pharm Res. 1999 Jul;16(7):1114-8
pubmed: 10450940
N Engl J Med. 2018 Jul 5;379(1):11-21
pubmed: 29972753
Eur J Pharm Biopharm. 2006 Nov;64(3):287-93
pubmed: 16949804
Adv Mater. 2010 Sep 22;22(36):4049-53
pubmed: 20665571
Int J Pharm. 2015 Apr 30;484(1-2):8-15
pubmed: 25701632
Colloids Surf B Biointerfaces. 2013 Jan 1;101:353-60
pubmed: 23010041
APL Bioeng. 2019 Mar 26;3(1):011502
pubmed: 31069332
RSC Adv. 2019 Aug 8;9(43):24699-24721
pubmed: 35528643
Vaccines (Basel). 2021 Jan 21;9(2):
pubmed: 33494530
Int J Nanomedicine. 2018 Aug 20;13:4727-4745
pubmed: 30154657
Cancer Chemother Pharmacol. 2015 May;75(5):1075-87
pubmed: 25898813
Int J Pharm. 2020 May 15;581:119275
pubmed: 32229283
Theranostics. 2016 Jun 07;6(9):1306-23
pubmed: 27375781
J Control Release. 2019 Aug 28;308:197-208
pubmed: 31195059
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):1437-1443
pubmed: 30991848
Bioconjug Chem. 2016 Dec 21;27(12):2874-2885
pubmed: 27998075
Clin Cancer Res. 2007 Oct 1;13(19):5855-61
pubmed: 17908979
Mol Pharm. 2015 Jul 6;12(7):2429-35
pubmed: 26070445
Int J Pharm. 2006 Nov 15;325(1-2):172-9
pubmed: 16887303
Pharm Res. 2007 Jun;24(6):1029-46
pubmed: 17385025
Int J Cancer. 2010 Mar 1;126(5):1235-45
pubmed: 19697323
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt A):28-51
pubmed: 26456916
Biologics. 2014 Feb 10;8:27-38
pubmed: 24596453
Invest New Drugs. 2017 Apr;35(2):180-188
pubmed: 27917453
Int J Pharm. 1999 Oct 5;187(2):143-52
pubmed: 10502620
Colloids Surf B Biointerfaces. 2016 Feb 1;138:1-9
pubmed: 26638176
Br J Cancer. 2004 Jun 1;90(11):2085-91
pubmed: 15150584
Anticancer Drugs. 2002 Oct;13(9):915-24
pubmed: 12394254
Adv Drug Deliv Rev. 2011 Jul 18;63(8):659-70
pubmed: 21333700
Leuk Res. 2003 Nov;27(11):1039-50
pubmed: 12859997
J Law Med Ethics. 2009 Winter;37(4):659-84
pubmed: 20122108
Int J Nanomedicine. 2015 Apr 24;10:3163-70
pubmed: 25995626
Ther Clin Risk Manag. 2008 Feb;4(1):269-86
pubmed: 18728716
Mater Sci Eng C Mater Biol Appl. 2017 Jul 1;76:1289-1304
pubmed: 28482496
Nat Rev Cancer. 2006 Sep;6(9):688-701
pubmed: 16900224
Hum Vaccin Immunother. 2014;10(11):3383-93
pubmed: 25483673
Biomater Sci. 2013 Apr 5;1(4):411-420
pubmed: 32481906
Clin Cancer Res. 2008 Mar 1;14(5):1310-6
pubmed: 18316549
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017 Jan;9(1):
pubmed: 27312983
J Control Release. 2005 Nov 28;108(2-3):244-62
pubmed: 16213056
Clin Cancer Res. 2020 Aug 15;26(16):4225-4232
pubmed: 32381487
Colloids Surf B Biointerfaces. 2015 Dec 1;136:1058-66
pubmed: 26590899
Drug Dev Ind Pharm. 2010 Nov;36(11):1377-87
pubmed: 20545520
Biotechnol Adv. 2014 Jul-Aug;32(4):778-88
pubmed: 24113214
Mol Pharm. 2018 Oct 1;15(10):4668-4676
pubmed: 30179491
Pharm Res. 2009 May;26(5):1162-71
pubmed: 19191012
Anticancer Res. 2014 Oct;34(10):5303-12
pubmed: 25275023
Pharmacol Res. 2016 Nov;113(Pt A):92-99
pubmed: 27546164
Cancer Biol Med. 2017 Nov;14(4):363-370
pubmed: 29372102
ESMO Open. 2017 Oct 23;2(4):e000238
pubmed: 29104762
Br J Cancer. 2005 Apr 11;92(7):1240-6
pubmed: 15785749
J Control Release. 2021 Jul 10;335:449-456
pubmed: 34029632
Drug Saf. 2015 May;38(5):455-79
pubmed: 25832756
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016 Mar-Apr;8(2):271-99
pubmed: 26314803
J Biomater Sci Polym Ed. 2001;12(1):21-34
pubmed: 11334187
Annu Rev Biomed Eng. 2012;14:1-16
pubmed: 22524388
Eur J Pharm Biopharm. 2012 Feb;80(2):241-6
pubmed: 21888972
Exp Hematol Oncol. 2012 Apr 23;1(1):10
pubmed: 23210520
Polymers (Basel). 2020 Dec 25;13(1):
pubmed: 33375759
J Control Release. 2014 Nov 10;193:122-38
pubmed: 24862321
Int J Nanomedicine. 2008;3(3):295-309
pubmed: 18990939
Biomaterials. 2000 Aug;21(16):1659-68
pubmed: 10905407
Drugs. 2015 Sep;75(14):1601-11
pubmed: 26323338
P T. 2017 Dec;42(12):742-755
pubmed: 29234213
Cancer Chemother Pharmacol. 2002 Apr;49(4):342-5
pubmed: 11914915
Adv Drug Deliv Rev. 2008 May 22;60(8):876-85
pubmed: 18423779
Small. 2014 Jul 9;10(13):2516-29
pubmed: 24687857
J Control Release. 2006 Jan 10;110(2):266-272
pubmed: 16300851
Int J Pharm. 2020 Jan 25;574:118849
pubmed: 31759108
ACS Nano. 2008 Aug;2(8):1696-702
pubmed: 19206374
Biomaterials. 2020 Feb;232:119706
pubmed: 31918220
Chem Commun (Camb). 2010 May 14;46(18):3167-9
pubmed: 20424762
J Clin Pharmacol. 2012 Feb;52(2):180-94
pubmed: 21233302
Nanoscale. 2014 Jan 7;6(1):65-75
pubmed: 24280870